Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.48 |
| ▸ | TACR3 | P29371 | 7/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927755 | 1.00 | ROCK1 (0.52) | ROCK1AKT1AKT3TACR3TACR2 | |
| SCHEMBL4926552 | 0.90 | AKT1 (0.51) | ROCK1AKT1AKT3TACR3HPGDS | |
| SCHEMBL4927274 | 0.90 | AKT1 (0.51) | ROCK1AKT1AKT3TACR3HPGDS | |
| SCHEMBL5005761 | 0.90 | AKT1 (0.51) | ROCK1AKT1AKT3TACR3HPGDS | |
| SCHEMBL4924499 | 0.85 | HDAC3 (0.57) | ROCK1AKT3HPGDSKDM4EALDH1A1 | |
| SCHEMBL4929904 | 0.85 | HDAC3 (0.57) | ROCK1AKT3HPGDSKDM4EALDH1A1 | |
| SCHEMBL14007219 | 0.85 | HPGDS (0.50) | AKT1TACR3TACR2HPGDSKDM4E | |
| SCHEMBL5226996 | 0.84 | AKT3 (0.52) | ROCK1AKT1AKT3TACR3CDC7 | |
| SCHEMBL13992686 | 0.82 | AKT3 (0.52) | AKT3LMNACDC7 | |
| SCHEMBL4990803 | 0.82 | AKT3 (0.52) | AKT3LMNACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1708697-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1708697-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005074642-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | CYP11B2, CYP11B1, REN | ROCK1 968/4885AKT1 1954/4885AKT3 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.